LILLY VET TO HEAD KHEPRIEli Lilly and Co. veteran Ronald D. Henriksen has just taken thereins of office at privately held Khepri Pharmaceuticals Inc. ofAlameda, Calif., as its president and chief executive officer.
As Lilly's director of business development, Henriksenevaluated new life science technologies for the pharmaceuticalcompany, and was responsible for negotiating R&D agreements,strategic alliances and equity transactions with biotechnologycompanies.
Henriksen will now head the fledgling biotechnology company,formed to capitalize on the role that proteases play incontrolling key biological processes. Khepri already hastechnology for engineering proteases and protease inhibitors astherapeutics, and a product portfolio that includes neutralendopeptidase, an enzyme involved in inflammatory processesthat it licensed from Genentech Inc., Khepri's corporate partner.
Cytocare Inc. of Irvine, Calif., appointed Kenneth Graziano vicepresident of regulatory affairs. Graziano was head of regulatoryaffairs for therapeutics at Hybritech Inc., an Eli Lilly and Co.subsidiary.
Colin Morris has joined Noven Pharmaceuticals Inc. of Miami asvice president of operations. He was senior director ofworldwide engineering for Rhone-Poulenc RorerPharmaceuticals.
Enzon Inc. of Piscataway, N.J., appointed Jose Gonzalez vicepresident of manufacturing. Gonzalez was associate director ofbioprocess research preparations at The Upjohn Co.
Craig McCarthy has joined the Institute for Biological Researchand Development (IBRD) of Irvine, Calif., as director ofregulatory affairs for the company's European division, basedin Cambridge, England. McCarthy was head of regulatoryaffairs for Roche Products Ltd.
HemaCare Corp. of Los Angeles, appointed Devra Shapiro vicepresident, finance and chief financial officer. Shapiro was vicepresident, corporate controller and chief accounting officer atEPIC Healthcare Group Inc. of Dallas.
AntiCancer Inc. of San Diego appointed to its scientific advisoryboard Sheldon Penman,professor of biology at MIT and amember of the National Academy of Sciences; Konrad Bloch,professor of chemistry at Harvard, a Nobel Laureate, and amember of the NAS; Morris Friedkin, professor of biology atUCSD and a member of the NAS; and Alex Varshavsky, biologyprofessor at Caltech.
Cell Genesys Inc. of Foster City, Calif., appointed Eugene Step toits board of directors. Step was executive vice president,president of the pharmaceutical division, and a member ofboard of directors at Eli Lilly and Co. until his retirement lastyear.
Separately, Cell GeneSys named Bridget Binko director ofregulatory affairs, David Broad director of cell culturedevelopment, and William Mueller director of process recovery.Binko was senior director of regulatory affairs and qualityassurance at Idec Pharmaceuticals Corp., Broad was aproduction manager at Celltech Ltd., and Mueller was managerof clinical manufacturing at Amgen Inc.
Deprenyl Research Ltd. of Toronto announced that its founder,Morton Shulman, has retired as co-chairman of the board andas a company director. Shulman stepped down as chiefexecutive officer last September. His son, Geoffrey Shulman,formerly co-chairman, will continue as chairman.
Allelix Biopharmaceuticals Inc. of Toronto appointed DigbyBarrios to its board of directors. Barrios was president andchief executive officer of Boehringer Ingelheim Corp.
Zonagen Inc. of The Woodlands, Texas, named to its board ofdirectors Robert Vukovich, the founder, chief executive officerand chairman of Roberts Pharmaceutical Corp.
(c) 1997 American Health Consultants. All rights reserved.